Muscarinic M1 acetylcholine receptor (M1R) neurons express the M1 subtype of muscarinic cholinergic receptors, which mediate critical cognitive functions including learning, memory consolidation, attention, and cortical activation. M1R signaling is profoundly impaired in Alzheimer's disease and represents a major therapeutic target for cognitive enhancement in neurodegenerative disorders.[1]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
The M1 receptor is a class A GPCR with distinctive features:[2]
| Property | Value |
|---|---|
| Gene | CHRM1 (chromosome 11q13) |
| Protein | 460 amino acids |
| Mass | ~51 kDa |
| Transmembrane domains | 7 |
| Signal transduction | Gq/11-coupled |
M1R activation triggers multiple downstream pathways:[3]
Classical Gq Pathway:
Ion Channel Modulation:
Gene Expression:
M1R is the most abundant muscarinic receptor in the brain:[4]
| Brain Region | Relative Expression | Primary Function |
|---|---|---|
| Cerebral cortex | Very high | Cognition, attention |
| Hippocampus | High | Memory consolidation |
| Striatum | High | Motor learning |
| Amygdala | Moderate | Emotional memory |
| Thalamus | Moderate | Sensory processing |
M1R is expressed on diverse cortical neuron populations:[5]
| Neuron Type | M1R Location | Function |
|---|---|---|
| Pyramidal neurons (L2/3) | Somatodendritic | Working memory |
| Pyramidal neurons (L5) | Somatodendritic | Motor output |
| Interneurons | Somatodendritic | Network modulation |
| Layer 5 corticospinal neurons | Dendritic | Excitability |
M1R modulates hippocampal circuits:[6]
M1R on striatal neurons modulates motor control:[7]
| Neuron Type | M1R Function | Clinical Relevance |
|---|---|---|
| Medium spiny neurons D1 | Inhibit DAT, increase DA | Direct pathway |
| Medium spiny neurons D2 | Indirect pathway modulation | Motor control |
| Cholinergic interneurons | Autoreceptor function | Motor learning |
M1R activation enhances synaptic plasticity:[8]
Long-Term Potentiation (LTP):
Long-Term Depression (LTD):
Spine Plasticity:
M1R shapes cortical rhythms:[9]
| Oscillation | Frequency | M1R Role |
|---|---|---|
| Gamma | 30-80 Hz | Generation, power enhancement |
| Theta | 4-8 Hz | Hippocampal theta modulation |
| Alpha | 8-12 Hz | Attention-related modulation |
M1R mediates cholinergic attention:[10]
M1R dysfunction is central to AD pathophysiology:[11]
Cholinergic Deficit:
Amyloid-β Effects on M1R:
Tau Pathology:
Cognitive Correlates:
M1R in PD cognitive impairment:[12]
M1R involvement in LBD:[13]
M1R dysfunction in HD:[14]
Multiple M1-selective agonists are in clinical development:[15]
| Compound | Mechanism | Status | Indication |
|---|---|---|---|
| HTL-0018318 | Orthosteric agonist | Phase II | AD, schizophrenia |
| KarXT (xanomeline + trospium) | M1/M4 agonist | FDA submitted | Schizophrenia, AD |
| GSK-103470 | Partial agonist | Phase II | AD cognitive |
| AZD-8529 | Positive allosteric modulator | Phase II | Cognitive disorders |
Current AD therapies enhance M1R signaling indirectly:[16]
| Drug | M1R Mechanism | Limitation |
|---|---|---|
| Donepezil | ↑ ACh → ↑ M1R activation | Non-selective, GI side effects |
| Rivastigmine | ↑ ACh → ↑ M1R activation | Patch delivery, weight loss |
| Galantamine | ↑ ACh + allosteric nAChR | Non-selective |
Selective M1 agonists offer advantages:[17]
M1R function can be enhanced by:[18]
| Marker | Type | Expression | Function |
|---|---|---|---|
| CHRM1 | Gene | Neurons, glia | M1 receptor |
| Phospho-CREB | Protein | Nucleus | M1R signaling readout |
| c-Fos | IEG | Nucleus | M1R activation marker |
| Gq/11α | G protein | Membrane | M1R coupling |
| PLCβ1 | Enzyme | Membrane | M1R signaling |
M1R-related cognitive domains:[19]
| Drug Class | Interaction with M1R | Clinical Consideration |
|---|---|---|
| Anticholinergics | M1R blockade | Cognitive impairment, delirium |
| Benzodiazepines | ↓ ACh release | Additive cognitive effects |
| Antipsychotics | Varying M1R affinity | Cognitive side effects |
| Opioids | ↓ ACh release | Sedation enhancement |
Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol. 2006. ↩︎
Haga K, et al. Structure of the human M1 muscarinic acetylcholine receptor bound to an allosteric modulator. Nature. 2013. ↩︎
Felder CC, et al. [Muscarinic acetylcholine receptors: signaling and relevance to CNS functions](https://doi.org/10.1016/S0928-4257(98). J Physiol Paris. 1998. ↩︎
Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1996. ↩︎
Dasilva M, et al. Layer-specific roles of M1 muscarinic acetylcholine receptors in the regulation of cortical circuit function. Cereb Cortex. 2021. ↩︎
Hasselmo ME, Giocomo LM. Cholinergic modulation of cortical function. J Mol Neurosci. 2006. ↩︎
Bonsi P, et al. Centrality of striatal cholinergic transmission in basal ganglia function. Front Neuroanat. 2011. ↩︎
Seeger T, et al. M1 muscarinic acetylcholine receptors modulate hippocampal synaptic plasticity. Eur J Neurosci. 2004. ↩︎
Fisahn A, et al. Distinct roles for M1 muscarinic and NMDA receptors in gamma-frequency oscillations in hippocampus. J Physiol. 2002. ↩︎
Herrero JL, et al. Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. Nature. 2008. ↩︎
Fisher A. M1 muscarinic agonists: their potential in the treatment of Alzheimer's disease. Biochem Soc Trans. 2008. ↩︎
Bohnen NI, et al. [Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches](https://doi.org/10.1016/S1474-4422(21). Lancet Neurol. 2022. ↩︎
Teaktong T, et al. Muscarinic M1 and M4 receptors in anterior cingulate cortex: relation to cognitive deficits in dementia with Lewy bodies. Neurobiol Aging. 2005. ↩︎
Van Raamsdonk JM, et al. Selective degeneration and nuclear localization of M1 muscarinic acetylcholine receptors in Huntington's disease. J Neurochem. 2007. ↩︎
Moran SP, et al. M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Neuropsychopharmacology. 2018. ↩︎
Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res. 2013. ↩︎
Kruse AC, et al. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov. 2017. ↩︎
Connelly PJ, et al. A randomized double-blind placebo-controlled trial of the muscarinic agonist xanomeline in Alzheimer disease. Alzheimer Dis Assoc Disord. 2009. ↩︎
Bentley P, et al. Cholinergic modulation of cognitive function in healthy subjects and dementia. Psychopharmacology (Berl). 2004. ↩︎